Exelixis Just Beat Again-So Why Leerink's Market Perform Downgrade Still Hurts

A solid quarter did not rescue the stock because investors now want the next growth signal

Another steady quarter did not rescue the stock because the upside case now depends on proof of the next leg, not confirmation of the last one. Exelixis still delivered $0.91 earnings per share and $628.69 million in revenue. That matters because it shows the business remains stable. But the market is no longer paying up for disciplined execution alone. It wants evidence that growth can broaden before it again rewards the company with a stability multiple.

That helps explain why the downgrade still matters. Leerink moved Exelixis to "Market Perform" from "Outperform", while the broader Street still sits near "Hold" at a $49.79 average target. In plain English, analysts are no longer signaling that a rerating is automatic. They are saying the next hurdle matters more than the last clean print.

If management can pair that operating discipline with a fresh sign of expansion, this selloff may look like a reset. If not, "solid again" becomes a story investors stop paying extra for.

Cabozantinib durability remains real, but it is no longer enough by itself

The downgrade looks less like a verdict on business fragility than on what kind of company the market believes Exelixis has become. A stable quarter matters because it keeps the platform intact. But a higher multiple usually goes to businesses that are proving a new growth vector, not just defending the old one.

Why "solid" stopped attracting a premium multiple

In the second quarter, cabozantinib U.S. net product sales accounted for $573.0 million of revenue. That is the operational proof point bulls have relied on for a long time. It is also why skeptics now question whether Exelixis deserves a rerating simply for doing what it has already been doing.

When a stock has been priced as a dependable compounder, steady execution supports the current multiple. To move above that, investors generally need evidence that the company can expand beyond a single product engine. Recent rating language reflects that boundary: Leerink cut Exelixis to "Market Perform" from "Outperform", even as the wider consensus remains "Hold".

The bull case rests on durability plus expansion

Bulls still have a reasonable case. Exelixis is not showing balance-sheet stress or strategic decay. The company has a perfect Piotroski Score of 9 and had previously reported 18.5% revenue growth over the last twelve months. The recent FDA approval of cabozantinib for neuroendocrine tumors also gives management another way to deepen the asset's lifetime value.

That matters because one-product winners can rerate when they show they are really one-product-many-frontiers winners.

What the market now needs to see

For the stock to move higher from here, Exelixis needs to turn baseline stability into visible expansion. The clearest signs would be:

• measurable revenue from the new NET indication,
• evidence that the business is becoming less dependent on cabozantinib's core run rate, and
• pipeline or commercial milestones that suggest a second growth pillar is becoming more than a concept.

Why the bear case does not require a collapse

Skeptics do not need a breakdown to stay right. They only need proof that cabozantinib's clinical benefit is harder to commercialize than hoped. Even Leerink noted a slight erosion in the overall survival hazard ratio from earlier ESMO data to the FDA approval, alongside safety issues that can complicate uptake.

If management adds measurable NET contribution soon, this downgrade may look premature. If not, the stock can remain fundamentally stable while staying psychologically capped.

Zanzalintinib is the real debate, even if the evidence is still early

From a wider angle, the real repricing trigger is not another beat. It is whether Exelixis can show a second growth pillar that changes how the market thinks about durability.

Why investor narratives can get ahead of the evidence

When a company keeps clearing the visible hurdle, the market tends to chase the last headline. In biotech, though, the next milestone often matters more than the last one, because value comes from what is still unproven rather than what has already been logged.

Right now, that next test is the non-cabozantinib growth path. Leerink's earlier Market Perform rating and $33 target around the NET label expansion is useful because it shows how the market can separate "good news" from "enough to rerate." The evidence supports the label expansion and its commercial relevance, but it does not by itself prove a new earnings leg is already here.

The real bull/bear split

This is where both sides can oversimplify. Bulls can read any label win as evidence that a new pillar is already inside the model. Bears can read the same thing and assume the company is still trapped in the old story. Both are simplifying.

The real debate is whether Exelixis can create another asset with enough clinical or commercial distinction to deserve a higher ceiling. That is a bigger question than whether the company can execute at a basic level.

What would change the tone here

If management keeps offering only narrative, investors will likely keep paying for safety rather than expansion. If it starts to add firmer evidence, this is where multiple expansion usually begins.

What would make the downgrade wrong over the next few months

Leerink's downgrade is not final proof that Exelixis has peaked. It is a statement that another quarter of clean execution is no longer enough to force a rerating. That matters because the firm cut the stock to "Market Perform" from "Outperform" even as the broader Street still sits in an "Hold" consensus.

Key signals to watch

• NET uptake. The new indication is real, but the data still leave room for skepticism, including a slight erosion in the overall survival hazard ratio. If the next update starts to show meaningful revenue from the NET indication, the market may finally see commercial traction rather than just label breadth.
• Zanzalintinib momentum. The key signal is not narrative alone. It is whether Exelixis can point to pivotal readouts or clear advancement milestones that push the program closer to commercial relevance.
• A second pillar, not just one asset. Another beat on the old script may be absorbed. What would make Leerink wrong is proof that growth can broaden.

My call is plain: wait-and-see unless management adds repeatable breakthroughs on top of steady execution.